Medication info

Ilseong Sitamet Tablets 50/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Sitagliptin Phosphate›62.04mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Ilseong IS Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/box [(10 tablets/PTP x 3 packs)]
Approval status
Expired

MFDS item code 201503333 · Approved 2015.05.29

This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one tablet of 50/500 mg twice daily. The dose may be increased to one tablet of 50/1000 mg twice daily. 2. Patients receiving metformin: The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the current metformin dose. Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with impaired hepatic function because it contains metformin.

Ingredients

Manufacturer
Ilseong IS Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood glucose control in patients with type 2 diabetes, by complementing diet and exercise therapy. The combination of sitagliptin and metformin works together to help manage blood sugar effectively. Therefore, consistent use can contribute to diabetes management.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one tablet of 50/500 mg twice daily. The dose may be increased to one tablet of 50/1000 mg twice daily. 2. Patients receiving metformin: The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the current metformin dose. Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with impaired hepatic function because it contains metformin.

Precautions

This medication contains both sitagliptin and metformin and is used for the treatment of type 2 diabetes. Firstly, severe allergic reactions may occur when taking this medication, so if symptoms such as skin rash or difficulty breathing occur, stop taking it immediately and consult a doctor. Additionally, there is a risk of pancreatitis, which is inflammation of the pancreas, so if abdominal pain, vomiting, or severe abdominal pain occurs after taking this medication, visit a hospital immediately. Due to the metformin component, there is a rare risk for lactic acidosis, a serious metabolic disturbance, so if symptoms such as difficulty breathing, muscle pain, fatigue, or abdominal pain appear, stop taking the medication immediately and inform medical personnel. This medication should not be used in patients with moderate to severe renal impairment, severe infections, heart failure, or in pregnant or breastfeeding women. If undergoing surgery or receiving diagnostic tests that use contrast agents, temporarily discontinue use and resume only after renal function has been confirmed as normal. This medication lowers blood sugar levels, so caution is required in cases of irregular meal intake or vigorous exercise as hypoglycemia may occur. Moreover, the risk of hypoglycemia may increase when taken with other blood glucose-lowering agents or alcohol, thus it is necessary to consult with a doctor for medication adjustments. Regular monitoring of renal function, blood tests, and vitamin B12 levels is necessary during the course of treatment, and any abnormal symptoms should be reported to medical personnel immediately. Finally, excessive alcohol consumption should be avoided while taking this medication, and a full understanding of the potential benefits and risks of the medication should be obtained before usage.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 23 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • blistering pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disorder
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container to prevent air exposure, and it is recommended to keep it at room temperature between 1 to 30 degrees Celsius. This storage method helps maintain the effectiveness of the medication and prevents deterioration.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/box [(10 tablets/PTP x 3 packs)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.